SCYNEXIS recalls BREXAFEMME and pauses Phase 3 MARIO study on cross-contamination risk

SCYNEXIS INC

GSK review found a beta-lactam drug manufactured on equipment shared with ibrexafungerp; potential cross-contamination risk.
No known contamination of ibrexafungerp and no adverse events reported; recall is out of caution.
Market recall of BREXAFEMME (ibrexafungerp tablets) and temporary hold on all clinical studies, including Phase 3 MARIO.
Mitigation strategy and resupply plan to be determined; ongoing collaboration with GSK.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.